Author:
Schcolnik-Cabrera Alejandro
Publisher
Springer Nature Singapore
Reference87 articles.
1. Cherla A, Renwick M, Jha A, Mossialos E (2020) Cost-effectiveness of cancer drugs: comparative analysis of the United States and England. EClinicalMedicine 29-30:100625
2. Hilal T, Gonzalez-Velez M, Prasad V (2020) Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration. JAMA Intern Med 180(8):1108–1115
3. Taylor SI (2020) The high cost of diabetes drugs: disparate impact on the most vulnerable patients. Diabetes Care 43(10):2330–2332
4. Miller BR, Nguyen H, Hu CJ, Lin C, Nguyen QT (2014) New and emerging drugs and targets for type 2 diabetes: reviewing the evidence. Am Health Drug Benef 7(8):452–463
5. Hodos RA, Kidd BA, Shameer K, Readhead BP, Dudley JT (2016) In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 8(3):186–210